HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is in discussions with potential marketing partners for the Company’s NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH), following the successful completion of a placebo-controlled, double-blind, multi-center Phase 2 trial.
